Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

October 11, 2013

James Domagalski Named to Legal Elite of Western New York

Buffalo, New York - October 11, 2013 - James P. Domagalski, Managing Director of the Hiscock & Barclay, LLP office in Buffalo, has been named to the Legal Elite of Western New York. Published by Buffalo Business First and The Buffalo Law Journal, the Legal Elite of Western New York 2013 included 124 attorneys from a record number of nominations.

Domagalski is part of the firm's Commercial Litigation, Construction & Surety and Labor & Employment practice areas. An attorney for more than 20 years, Domagalski has represented municipalities, manufacturers, contractors, engineering firms and the federal government, among others.

"It is a high honor to be listed among the top people in our legal community," said Domagalski. "I thank those who nominated me and I thank the people at The Buffalo Law Journal and Business First for their careful and consistent reporting on our industry."

Hiscock & Barclay, LLP, listed as a "Top 250 Firm" by The National Law Journal, is a full-service, 200-attorney law firm, with offices throughout the major cities of New York State, as well as in Boston, Washington, Newark, N.J. and Toronto, providing comprehensive legal and business counsel to a diverse client base in 30 practice areas.

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks